SG11202108764SA - Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof - Google Patents

Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof

Info

Publication number
SG11202108764SA
SG11202108764SA SG11202108764SA SG11202108764SA SG11202108764SA SG 11202108764S A SG11202108764S A SG 11202108764SA SG 11202108764S A SG11202108764S A SG 11202108764SA SG 11202108764S A SG11202108764S A SG 11202108764SA SG 11202108764S A SG11202108764S A SG 11202108764SA
Authority
SG
Singapore
Prior art keywords
mepe
variants
matrix extracellular
extracellular phosphoglycoprotein
phosphoglycoprotein
Prior art date
Application number
SG11202108764SA
Inventor
Joshua Backman
Aris Baras
Aris Economides
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202108764SA publication Critical patent/SG11202108764SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202108764SA 2019-02-18 2020-02-07 Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof SG11202108764SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806939P 2019-02-18 2019-02-18
US201962862842P 2019-06-18 2019-06-18
PCT/US2020/017189 WO2020171979A1 (en) 2019-02-18 2020-02-07 Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof

Publications (1)

Publication Number Publication Date
SG11202108764SA true SG11202108764SA (en) 2021-09-29

Family

ID=69771167

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108764SA SG11202108764SA (en) 2019-02-18 2020-02-07 Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof

Country Status (11)

Country Link
US (1) US20200263251A1 (en)
EP (1) EP3927843A1 (en)
JP (1) JP2022520660A (en)
KR (1) KR20210136037A (en)
CN (1) CN113544285A (en)
AU (1) AU2020224073A1 (en)
CA (1) CA3130092A1 (en)
IL (1) IL285622A (en)
MX (1) MX2021009979A (en)
SG (1) SG11202108764SA (en)
WO (1) WO2020171979A1 (en)

Also Published As

Publication number Publication date
AU2020224073A1 (en) 2021-09-16
US20200263251A1 (en) 2020-08-20
IL285622A (en) 2021-09-30
CN113544285A (en) 2021-10-22
WO2020171979A1 (en) 2020-08-27
KR20210136037A (en) 2021-11-16
JP2022520660A (en) 2022-03-31
EP3927843A1 (en) 2021-12-29
MX2021009979A (en) 2021-12-10
AU2020224073A8 (en) 2021-10-07
CA3130092A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
ZA202203580B (en) Il-17a modulators and uses thereof
IL287781A (en) Clec12a-binding polypeptides and uses thereof
EP3985014A4 (en) Romo1-derived antimicrobial peptides and variants thereof
SG11202111711PA (en) Cd33-binding polypeptides and uses thereof
GB201813678D0 (en) Acylated calcitonin mimetics
ZA202203618B (en) Mmup monomer variant and application thereof
ZA202203568B (en) Mnep monomer variant and application thereof
PL4013969T3 (en) Tightening element
GB2567869B (en) Toughened humidity/thermal resistant cyanoacrylate compositions
CA187196S (en) Wearable blanket
IL287753A (en) Masp inhibitory compounds and uses thereof
EP3706771A4 (en) Bcl9 peptides and variants thereof
EP4047057A4 (en) Quencher and uses thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
EP4006048A4 (en) Novel micropeptide hmmw and application thereof
IL285622A (en) Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof
GB201909053D0 (en) Compression
EP3804498A4 (en) Threshing cylinder
EP3994582A4 (en) Hardware-based memory compression
IL290003A (en) A tissue-adhesive matrix and uses thereof
IL277441A (en) Lfa3 variants and compositions and uses thereof
GB202204420D0 (en) Crypto-erasure via internal and/or external action
GB201913168D0 (en) Fingernail display system
GB201905509D0 (en) Pharmaceutical compositions and associated lits and uses